Loading patent…
AssigneesNanyang Technological University, National Skin Center (S) Pte Ltd
InventorsSierin LIM, Sathyamoorthy BHASKAR, Steven THNG, Ambili KUNIYIL, Sarker MRIDUL
Estimating the term…
The present invention relates to protein nanocages comprising a melanocyte-targeting moiety and pharmaceutical compositions comprising the protein cages as well as methods for treating or diagnosing hyperpigmentation disorders or other melanocyte-related disorders using the protein nanocages or pharmaceutical compositions. In the preferred embodiment, the protein nanocage is composed of Bacillus stearothermophilus E2 protein of pyruvate dehydrogenase multi-enzyme complex (E2), with a skin penetrating and cell permeating SPACE moiety, and a melanocyte-targeting moiety of alpha melanocyte stimulating hormone.
A protein nanocage comprising a melanocyte-targeting moiety, wherein the melanocyte-targeting moiety is coupled to the exterior surface of the protein nanocage.
A pharmaceutical or cosmetic composition comprising a protein nanocage comprising a melanocyte-targeting moiety and a pharmaceutically acceptable carrier, wherein the melanocyte-targeting moiety is coupled to the exterior surface of the protein nanocage.
A method for treating or diagnosing hyperpigmentation disorders or other melanocyte-related disorders in a subject, comprising administering to said subject an effective amount of a protein nanocage comprising a melanocyte-targeting moiety or a pharmaceutical or cosmetic composition comprising the protein nanocage comprising a melanocyte-targeting moiety and a pharmaceutically acceptable carrier, wherein the melanocyte-targeting moiety is coupled to the exterior surface of the protein nanocage, the subject being a mammal.
(canceled)
(canceled)
Dependencies are inferred from the claim text.